Accession Number:



Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

Descriptive Note:

Technical Report,30 Sep 2016,29 Sep 2017

Corporate Author:

Johns Hopkins University Baltimore United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Cognitive dysfunction is common and devastating to people with multiple sclerosis MS. To date, multiple pharmacologic interventions have been tried for MS-related cognitive dysfunction with disappointing results. Hence, there is an urgent need to identify or develop novel therapies that can help improve cognitive function in MS. This clinical trial is designed to evaluate the safety, tolerability, and efficacy of intranasal insulin in cognitively impaired people with MS. The study will also evaluate the impact of intranasal insulin on measures of oxidative stress, axonal injury, cellular stress, and energy metabolism in MS. The design of this phase III, randomized, double-blind, placebo-controlled trial is as follows 105participants will be randomized 111, stratified by relapsing versus progressive MS to intranasal insulin 10 international units IU twice a day, 20 IU twice a day, or placebo for 24weeks. Insulin will be administered intranasally to allow direct delivery of the medication into the central nervous system.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: